Advised on the University’s role acting as a local sponsor for a phase II clinical trial. Our advice made recommendations on the contractual, structural and regulatory arrangements that should be put in place to manage risk and achieve compliance. We also reviewed and advised on amendments to draft contractual documentation provided by the overseas sponsor, including with respect to the ownership and licensing of intellectual property rights produced during the clinical trial.